JNK

Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024

Retrieved on: 
Friday, March 8, 2024
Assay, Cancer, JNK, NLRP3, AACR, IIS, Biochemistry, Cellular, Therapy, Reactive oxygen species, Tumor microenvironment, Patient, ROS, Research, Pharmaceutical industry

“The ability to impact multiple targets is an important characteristic of Onconova’s two lead clinical programs, rigosertib and narazaciclib.

Key Points: 
  • “The ability to impact multiple targets is an important characteristic of Onconova’s two lead clinical programs, rigosertib and narazaciclib.
  • We are pleased to present new preclinical studies that explore the molecular targets for rigosertib, in clinical development through a series of investigator initiated studies (IIS),” commented Steven Fruchtman, M.D., President and Chief Executive Officer of Onconova.
  • “The studies provide additional prospective on the main cellular pathways impacted by rigosertib, including RAS-MAPK signaling and reactive oxygen species (ROS)-related proteins.
  • Conclusions: This work identified a series of cellular and inflammatory targets that may be affected by rigosertib.

Onconova Therapeutics Presents Preclinical Data Characterizing Rigosertib’s Mechanisms of Action at the AACR Targeting RAS Conference

Retrieved on: 
Tuesday, March 7, 2023
Trigger, Protein, Mitosis, Growth, Cell division, Reactive oxygen species, ROS, Cancer, Lung cancer, FDA, Poster, NLRP3, Therapy, RAS, Conference, AACR, NQO2, Microtubule, Patient, KRAS, JNK, Vaccine, Pharmaceutical industry

NEWTOWN, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced new preclinical data characterizing rigosertib’s mechanisms of action in a poster at the American Association for Cancer Research Special Conference on Targeting RAS (AACR Targeting RAS Conference).

Key Points: 
  • “The preclinical results presented at the Targeting RAS Conference increase our understanding of rigosertib’s anti-cancer effects and thereby represent a valuable tool to inform its continued clinical development,” said Mark Gelder, M.D., Chief Medical Officer of Onconova.
  • “I am particularly encouraged by data showing rigosertib-induced activation of the NLRP3 inflammasome.
  • Additional data identified the proteins NQO2, ERO1A, and NEK7 as potential novel targets that may be modulated by rigosertib.
  • Activation of NQO2 and/or ERO1A leads to reactive oxygen species (ROS)-induced activation of JNK signaling, which in-turn leads to RAS-MAPK pathway inhibition.

Altamira Therapeutics to Participate at RNA Leaders USA Congress

Retrieved on: 
Thursday, October 13, 2022
ETS, Congress, Securities Act of 1933, Disease, Therapy, RNA transfection, SEC, Rheumatoid arthritis, Vertigo, Virus, Vaccine, Oligonucleotide, Person, Annual report, RNA interference, Semaphore, RNA, Securities & Exchange Commission of Pakistan, RAS, Allergen, AM-411, Nasdaq, KRAS, Technology, Colonnade Hotel (Seattle), Tinnitus, Company, Sirna, Hearing loss, JNK, MD, Pathology, U.S. Securities and Exchange Commission, Securities Exchange Act of 1934, Forward-looking statement, Nasal spray, Terminology, TAM, Risk, Pharmaceutical industry, Medical imaging

The RNA Leaders USA Congress focuses on the scientific, clinical and commercial development of RNA therapeutics and vaccines.

Key Points: 
  • The RNA Leaders USA Congress focuses on the scientific, clinical and commercial development of RNA therapeutics and vaccines.
  • Altamira Therapeutics (Nasdaq: CYTO) is dedicated to developing therapeutics that address important unmet medical needs.
  • Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira Therapeutics' strategies or expectations.
  • All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or to persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to these risks and uncertainties.

Altamira Therapeutics to Participate in the 4th Annual RAS-Targeted Drug Development Summit

Retrieved on: 
Thursday, September 8, 2022
RNA interference, CEO, RNA, Rheumatoid arthritis, Forum, Securities Exchange Act of 1934, Securities Act of 1933, Therapy, NASDAQ, Disease, Semaphore, Virus, Risk, Person, Vertigo, Securities & Exchange Commission of Pakistan, SEC, Drug development, JNK, Allergen, Sirna, MD, KRAS, Oligonucleotide, Pancreas, Company, Tinnitus, TAM, Cancer, RAS, Hearing loss, U.S. Securities and Exchange Commission, Terminology, RNA transfection, Annual report, Industry, Nasal spray, Forward-looking statement, Patient, ETS, Pharmaceutical industry, Medical device, Vaccine

Altamira Therapeutics ("Altamira" or the "Company")(NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it will participate in-person at the 4th Annual RAS-Targeted Drug Development Summit being held on September 26-28, 2022 in Boston, Massachusetts.

Key Points: 
  • Altamira Therapeutics ("Altamira" or the "Company")(NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it will participate in-person at the 4th Annual RAS-Targeted Drug Development Summit being held on September 26-28, 2022 in Boston, Massachusetts.
  • The 4th RAS-Targeted Drug Development Summit is the only industry-focusedwholly dedicated forum for the global community of individuals committed to targeting RAS-mutant cancers.
  • Altamira Therapeutics (NASDAQ:CYTO) is dedicated to developing therapeutics that address important unmet medical needs.
  • All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or to persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to these risks and uncertainties.

BioVie and Dr. Sheldon Jordan Jointly Announce Topline Results from an Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer’s Disease

Retrieved on: 
Wednesday, September 7, 2022
Interferon gamma, Inflammation, Insulin resistance, AES, Treatment, Rheumatoid arthritis, Alzheimer's disease, Research, NASDAQ, Cognition, Glossary of biology, Dementia, Global, NF-κB, Psoriasis, IL23, Cytokine, JNK, Patent, TNF, Neurotoxicity, ADAS, GLOBE, MCI, Neuroinflammation, Mini–Mental State Examination, Use, Conference, TNFR1, Company, Placebo, Immune system, Phosphorylation, Annual conferences, Biomarker, Patrick Groc, AD, IKK, ERK, MMSE, Oxidative stress, Patient, Medicine, Pharmaceutical industry, Tumor necrosis factor

Reductions in TNFa (considered to be an initial factor driving inflammation) after NE3107 treatment are significantly correlated with improvement in cognition.

Key Points: 
  • Reductions in TNFa (considered to be an initial factor driving inflammation) after NE3107 treatment are significantly correlated with improvement in cognition.
  • NE3107 is the only molecule in this group that is pursuing a two-pronged approach targeting both neuroinflammation and insulin resistance.
  • Initial results showed that the measurements for most patients improved with NE3107 treatment, although MCI/mild AD patients showed greater change.
  • The Phase 2 trial (NCT05083260) is enrolling 40 patients to examine NE3107 in Parkinsons disease (PD) with two design objectives.